Carcinoembryonic antigenrelated cell adhesion molecule 8 (CEACAM8)

Links to databases

Wikipedia
Uniprot P31997

CEACAM8 (also known as Cluster of Differentiation 66b, CD66b) finctions in cell adhesion, cell migration, and pathogen binding. It is expressed exclusively on granulocytes and is used as granulocyte marker.

Sample type

Analytical Measuring Range

Please note: the technical data reported below refers to the measured value in the in vitro validation assays. The calibrator curve below shows the performance of the assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens. Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please visit our FAQ page (https://www.olink.com/question/what-is-npx).

- LOD (pg/mL)
- 244.14
- LLOQ (pg/mL)
- 244.14
- ULOQ (pg/mL)
- 250000
- Hook (pg/mL)
- 1000000
- Range (logs)
- 3

Calibrator curve for validation data (generated in multiplex)

Carcinoembryonic antigenrelated cell adhesion molecule 8 (CEACAM8)

Precision

- Within run precision Coefficient of Variation (CV)
- 11%
- Between run precision Coefficient of Variation (CV)
- 10%

Precision (repeatability) is calculated from linearized NPX values over LOD.

Biomarker Validation Data

Additional validation data, as well as a more detailed description of how the Olink panels are quality controlled can be found in our Data Validation documents. To download or to learn more go to the Data Validation page.

View all CVD II panel biomarkers >

View all biomarkers >

品牌介绍

Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our high quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015.Following a company reorganization in April, 2016, Olink Proteomics is focusing entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery, while Olink Bioscience is responsible for the development and commercialization of the remaining extensive and expanding, diverse Olink IP portfolio. (You can read the press release here).